Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

Cancer

Volumn 97, Issue 5, 2003, Pages 1248-1252

  Verstovsek, Srdan ^a   Kantarjian, Hagop ^a   Manshouri, Taghi ^a   Cortes, Jorge ^a   Faderl, Stefan ^a   Giles, Francis J ^a   Keating, Michael ^a   Albitar, Maher ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Accelerated blastic phase chronic myeloid leukemia (A BP CML); Chronic phase chronic myeloidleukemia (CP CML); Prognosis; Telomerase activity (TA)

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DAUNORUBICIN; HEMOGLOBIN; REPETITIVE DNA; TELOMERASE; TELOMERASE INHIBITOR;

ADULT; ADVANCED CANCER; AGE; ARTICLE; BASOPHIL; BLAST CELL; BONE MARROW; BONE MARROW CELL; CANCER SURVIVAL; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; GENE AMPLIFICATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; TREATMENT INDICATION;

AGED; BONE MARROW; HUMANS; LEUKEMIA, MYELOID, CHRONIC; POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TELOMERASE;

EID: 0037369162     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11217     Document Type: Article

References (19)

1. Elenitoba-Johnson KS. Complex regulation of telomerase activity: implications for cancer therapy. Am J Pathol. 2001; 159:405-410.
2. Helder MN, Wisman GB, van der Zee GJ. Telomerase and telomeres: from basic biology to cancer treatment. Cancer Invest. 2002;20:82-101.
3. Perry PJ, Arnold JR, Jenkins TC. Telomerase inhibitors for the treatment of cancer: the current perspective. Expert Opin Investig Drugs. 2001;10:2141-2156.
4. Bitisik O, Yavuz S, Yasasever V, Dalay N. Telomerase activity in patients with chronic myeloid leukemia and lymphoma. Res Commun Mol Pathol Pharmacol. 2000;107:3-12.
5. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000;60:610-617.
6. Li G, Song YH, Qian LS, Ma XT, Wu KF. Telomerase: obviously activated in the accelerated phase of chronic myeloid leukemia. Haematologica. 2000;85:1222-1224.
7. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia. 1997;11:190-194.
8. Tatematsu K, Nakayama J, Danbara M, et al. A novel quantitative 'stretch PCR assay' that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene. 1996;13:2265-2274.
9. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A. 1995;92:9082-9086.
10. Verstovsek S, Manshouri T, Kantarjian H, et al. Highly reproducible detection and semi-quantification of telomerase activity. Biotechniques. 2001;30:930-934.
11. Kantarjian HM, Keating MJ, Smith TL, et al. Proposal for a simple prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
12. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883-1890.
13. Boultwood J, Fidler C, Shepherd P, et al. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol. 1999;61:5-9.
14. Boultwood J, Peniket A, Watkins F, et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood. 2000;96:358-361.
15. Iwama H, Ohyashiki K, Ohyashiki JH, et al. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia. Cancer. 1997;79:1552-1560.
16. Nilsson P, Mehle C, Remes K, Roos G. Telomerase activity in vivo in human malignant hematopoietic cells. Oncogene. 1994;9:3043-3048.
17. Ohyashiki JH, Hayashi S, Yahata N, et al. Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells. Int J Oncol. 2001;18:593-598.
18. Ohyashiki K, Iwama H, Tauchi T, et al. Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia. Leuk Lymphoma. 2000;40:49-56.
19. Hayashi S, Iwama H, Yahata N, Ando K, Ohyashiki JH, Ohyashiki K. Malignancy: subsequential alterations of telomeric DNA length correlate with cytogenetic response in chronic myeloid leukemia treated with interferon alpha. Hematology. 1999;4:1-10.